Daylight Partners

Daylight Capital's public materials reference a focus on emerging technologies within the biotechnology sector broadly. It does not break down specific therapeutic areas or modalities, such as gene editing or oncology, on its website. The firm's investment thesis centers on data interpretation to predict regulatory outcomes rather than on any single scientific niche.

The firm describes its approach as using value investing principles to mitigate the inherent binary risk in biotech. It aims to identify opportunities where the market has mispriced the likelihood of regulatory approval or a positive catalytic event. This event-driven strategy attempts to capture returns from discrete milestones rather than long-term drug development.

The firm's public presence is minimal, with no marketing materials or investor portals advertising open fundraising. Its Evansville Fund landing page provides a subscription link for more information, suggesting qualified investors can inquire, but no minimums, liquidity terms, or performance records are disclosed publicly.

The firm's website carries the title 'Evansville Fund' and references 'Daylight Capital, a biotech investment hedge fund located in Evansville Indiana.' However, Altss research places its primary headquarters in Austin, Texas. This connection may represent the firm's original founding location or a historic office before a relocation to Austin, though the firm does not clarify the current operational split.

Daylight Capital discloses no named principals, portfolio managers, or analysts on its website. No LinkedIn page was captured in Altss research, and no regulatory filings or press releases naming its founders or investment committee members were located. The firm's leadership structure remains entirely opaque.